Eliem Therapeutics Inc (NASDAQ: ELYM) is 85.19% higher on its value in year-to-date trading and has touched a low of $2.35 and a high of $11.55 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ELYM stock was last observed hovering at around $5.50 in the last trading session, with the day’s loss setting it -0.5%.
Currently trading at $5.00, the stock is -33.40% and -30.84% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.33 million and changing -9.09% at the moment leaves the stock -6.02% off its SMA200. ELYM registered 91.57% gain for a year compared to 6-month gain of 81.16%. The firm has a 50-day simple moving average (SMA 50) of $7.1924 and a 200-day simple moving average (SMA200) of $5.33634.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -17.63% loss in the last 1 month and extending the period to 3 months gives it a -33.60%, and is -39.61% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 21.62% over the week and 11.53% over the month.
Eliem Therapeutics Inc (ELYM) has around 9 employees, a market worth around $335.30M and $0.00M in sales. Distance from 52-week low is 112.77% and -56.71% from its 52-week high. The company has generated returns on investments over the last 12 months (-28.88%).
68.0 institutions hold shares in Eliem Therapeutics Inc (ELYM), with institutional investors hold 86.67% of the company’s shares. The shares outstanding are 67.06M, and float is at 51.90M with Short Float at 2.22%. Institutions hold 77.67% of the Float.
The top institutional shareholder in the company is RA CAPITAL MANAGEMENT, L.P. with over 31.42 million shares valued at $223.39 million. The investor’s holdings represent 103.5246 of the ELYM Shares outstanding. As of 2024-06-30, the second largest holder is DEEP TRACK CAPITAL, LP with 3.9 million shares valued at $27.76 million to account for 12.866 of the shares outstanding. The other top investors are SAMSARA BIOCAPITAL, LLC which holds 3.26 million shares representing 10.7461 and valued at over $23.19 million, while JANUS HENDERSON GROUP PLC holds 10.7217 of the shares totaling 3.25 million with a market value of $23.14 million.
Eliem Therapeutics Inc (ELYM) Insider Activity
The most recent transaction is an insider sale by Pimblett Emily, the company’s CHIEF ACCOUNTING OFFICER. SEC filings show that Pimblett Emily sold 1,191 shares of the company’s common stock on Sep 20 ’24 at a price of $8.18 per share for a total of $9741.0. Following the sale, the insider now owns 7564.0 shares.
Eliem Therapeutics Inc disclosed in a document filed with the SEC on Jul 22 ’24 that Morisset Valerie (EVP, R&D AND CSO) sold a total of 69,005 shares of the company’s common stock. The trade occurred on Jul 22 ’24 and was made at $8.03 per share for $0.55 million. Following the transaction, the insider now directly holds 31317.0 shares of the ELYM stock.
Still, SEC filings show that on Jul 19 ’24, Morisset Valerie (EVP, R&D AND CSO) disposed off 60,201 shares at an average price of $7.21 for $0.43 million. The insider now directly holds 100,322 shares of Eliem Therapeutics Inc (ELYM).
